Is RLFTD or DVY a better dividend investment in 2026?

RLFTD currently yields 49.02% with a 5% 5-year dividend growth rate. DVY yields 3.50% with 5% growth. The better choice depends on your goal: RLFTD offers higher current income.

What is the dividend yield difference between RLFTD and DVY?

RLFTD has a forward dividend yield of 49.02% ($2.00/share annually). DVY yields 3.50% ($5.25/share annually). The yield gap is 45.52 percentage points.

Home › Compare › RLFTD vs DVY

RLFTD vs DVY: Dividend Comparison 2026

RLFTD yields 49.02% · DVY yields 3.50%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RLFTD wins by $349.4K in total portfolio value

INVESTMENT

TIME HORIZON10 years

RLFTD

● Live price

49.02%

Share price

$4.08

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$374.5K

Annual income

$74,708.98

Full RLFTD calculator →

DVY

● Live price

3.50%

Share price

$150.03

Annual div

$5.25

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.1K

Annual income

$437.78

Full DVY calculator →

Portfolio growth — RLFTD vs DVY

📍 RLFTD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	RLFTD	DVY
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, RLFTD + DVY cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

RLFTD pays

DVY pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLFTD

Annual income on $10K today (after 15% tax)

$4,166.67/yr

After 10yr DRIP, annual income (after tax)

$63,502.63/yr

DVY

Annual income on $10K today (after 15% tax)

$297.17/yr

After 10yr DRIP, annual income (after tax)

$372.11/yr

At 15% tax rate, RLFTD beats the other by $63,130.52/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLFTD + DVY for your $10,000?

RLFTD: 50%DVY: 50%

100% DVY50/50100% RLFTD

Portfolio after 10yr

$199.8K

Annual income

$37,573.38/yr

Blended yield

18.81%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLFTD buys

DVY buys

No recent congressional trades found for RLFTD or DVY in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricRLFTDDVY

Forward yield	49.02% ✓	3.50%
Annual dividend / share	$2.00	$5.25 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$374.5K ✓	$25.1K
Annual income after 10y	$74,708.98 ✓	$437.78
Total dividends collected	$297.4K ✓	$4.0K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: RLFTD vs DVY ($10,000, DRIP)

Year	RLFTD Portfolio	RLFTD Income/yr	DVY Portfolio	DVY Income/yr	Gap
1← crossover	$15,602	$4,901.96	$11,050	$349.62	+$4.6K → RLFTD
2	$23,842	$7,147.68	$12,184	$361.04	+$11.7K → RLFTD
3	$35,719	$10,208.01	$13,409	$372.07	+$22.3K → RLFTD
4	$52,512	$14,292.70	$14,730	$382.68	+$37.8K → RLFTD
5	$75,825	$19,637.72	$16,154	$392.89	+$59.7K → RLFTD
6	$107,634	$26,501.16	$17,688	$402.69	+$89.9K → RLFTD
7	$150,326	$35,157.45	$19,338	$412.07	+$131.0K → RLFTD
8	$206,739	$45,889.95	$21,113	$421.04	+$185.6K → RLFTD
9	$280,193	$58,982.29	$23,020	$429.61	+$257.2K → RLFTD
10	$374,515	$74,708.98	$25,070	$437.78	+$349.4K → RLFTD

RLFTD vs DVY: Complete Analysis 2026

RLFTD — Stock

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

Full RLFTD Calculator →

DVY — ETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →

📬

Get this RLFTD vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLFTD vs SCHD RLFTD vs JEPI RLFTD vs O RLFTD vs KO RLFTD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.